What is the Fiscal Year for Outlook Therapeutics?
Date: November 13, 2026
Outlook Therapeutics's current fiscal year starts on October 1, 2026, and ends on September 30, 2027. Their current quarter is Q1, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
October 1, 2026
Fiscal Year End
September 30, 2027
Current Quarter
Q1
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Oct 1, 2026 – Dec 31, 2026
Q2
Jan 1, 2027 – Mar 31, 2027
Q3
Apr 1, 2027 – Jun 30, 2027
Q4
Jul 1, 2027 – Sep 30, 2027
Company Information
Headquarters
New Jersey, United States
Industry
Biotechnology Research
Stock Symbol
OTLK
Description
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg (U.S.), bevacizumab gamma (E.U.)). LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive U.S. FDA approval and European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany, Austria, and the UK as a treatment for wet AMD.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Outlook Therapeutics and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.